HighMark Wealth Management’s Relay Therapeutics RLAY Stock Holding History

HighMark Wealth Management’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-700	Closed	-$10.5K	–	611
2022 Q4	$10.5K	Sell	700 -205	-23%	-$3.92K	0.01%	247
2022 Q3	$20K	Hold	905	–	–	0.02%	164
2022 Q2	$15K	Hold	905	–	–	0.01%	198
2022 Q1	$27K	Hold	905	–	–	0.02%	148
2021 Q4	$28K	Sell	905 -1,700	-65%	-$53.7K	0.02%	151
2021 Q3	$87K	Buy	2,605 +209	+9%	+$7.04K	0.06%	85
2021 Q2	$88K	Buy	+2,396	New	+$79K	0.06%	84

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

HighMark Wealth Management's RLAY Position: Q1 2023 in Review

HighMark Wealth Management sold out of Relay Therapeutics (RLAY) in Q1 2023, closing a stake of 700 shares — an estimated $10.5K sold.

HighMark Wealth Management first reported a position in RLAY in Q2 2021 and held it in 7 quarters. The position peaked at $88K in Q2 2021. 157 funds tracked by Wall St. Rank hold RLAY as of Q1 2023.

HighMark Wealth Management reported no remaining Relay Therapeutics position as of Q1 2023 after selling out during the quarter.
HighMark Wealth Management sold 700 Relay Therapeutics shares in Q1 2023, an estimated $10.5K.
HighMark Wealth Management first reported a position in Relay Therapeutics in Q2 2021 and held it in 7 quarters.
HighMark Wealth Management's Relay Therapeutics position peaked at $88K in Q2 2021.
157 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2023.

Based on HighMark Wealth Management's 13F filing for Q1 2023, filed 21 Apr 2023.